Results 121 to 130 of about 20,878 (216)

Supplementary Figure Legends from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia [PDF]

, 2023
Nakhle S. Saba, Deanna H. Wong, Georges Tanios, Jessica R. Iyer, Patricia Lobelle‐Rich, Eman L. Dadashian, Delong Liu, Lorena Fontán, Erik K. Flemington, Cydney Nichols, Chingiz Underbayev, Hana Safah, Ari Melnick, Adrian Wiestner, Sarah E.M. Herman   +14 more
openalex   +1 more source

BTK inhibitor ibrutinib reduces LPS-induced inflammation in C8-B4 microglia. [PDF]

EXCLI J
Das D, Mali AS, Greco D, Michalicková D, Novotný J, Slanar O.   +5 more
europepmc   +1 more source

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia [PDF]

, 2018
Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Nyla A. Heerema, Corinne Hoffman, Gerard Lozanski, Kami J. Maddocks, Mollie E. Moran, Mark A. Reid, Margaret S. Lucas, Jennifer A. Woyach, W. Thomas Whitlow, Jeffrey A. Jones, John C. Byrd   +14 more
openalex   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

, 2018
Anita Kumar, Santosha A. Vardhana, Alison J. Moskowitz, Pierluigi Porcu, Ahmet Doğan, Jason A. Dubovsky, Matthew J. Matasar, Zhigang Zhang, Anas Younes, Steven M. Horwitz   +9 more
openalex   +1 more source

Ibrutinib in Refractory Classic Hodgkin's Lymphoma [PDF]

, 2015
Mehdi Hamadani, Sriram Balasubramanian, Parameswaran Hari   +2 more
openalex   +1 more source

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. [PDF]

Sci Rep
Khan A, Ali SS, Zahid MA, Alshabrmi FM, Al-Zoubi RM, Shkoor M, Mohammmad A, Wei DQ, Agouni A.   +8 more
europepmc   +1 more source

Data from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia

, 2023
Beatrice Del Papa, Stefano Baldoni, Erica Dorillo, Filomena De Falco, Chiara Rompietti, Debora Cecchini, Maria Grazia Cantelmi, Daniele Sorcini, Manuel Nogarotto, Francesco Maria Adamo, Federica Mezzasoma, Estevão Carlos Silva Barcelos, Elisabetta Albi, Roberta Iacucci Ostini, Ambra Di Tommaso, Andrea Marra, Guido Montanaro, Maria Paola Martelli, Franca Falzetti, Mauro Di Ianni, Emanuela Rosati, Paolo Sportoletti   +21 more
openalex   +1 more source

Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population. [PDF]

Hemasphere
Ghia P, Ysebaert L, Janssens A, Stilgenbauer S, Fouad M, Schioppa CA, Hernández-Rivas JÁ, Tedeschi A.   +7 more
europepmc   +1 more source

[Application of ibrutinib in primary central nervous system lymphoma].

, 2020
Diwen Pang, F L Chen, W Y Li
openalex   +2 more sources